Search

Your search keyword '"Zhang, Chun-Xiao"' showing total 213 results
Start Over Author "Zhang, Chun-Xiao"
213 results on '"Zhang, Chun-Xiao"'

11. Improving the structure and cycling stability of Ni-rich cathodes by dual modification.

Author

Zhu, Zhen-hua, Xu, Shi-jie, Zhang, Qiang-feng, Zhu, Hai-peng, Mei, Lin, and Zhang, Chun-xiao

Abstract

Copyright of Journal of Central South University is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

15. Recent progress in ether-based electrolytes for high-voltage lithium metal batteries

Author

ZHU, Hai-peng, ZHANG, Qiang-feng, CHEN, Zhao, PENG, Zi-yu, MEI, Lin, ZHANG, Chun-xiao, and WEI, Wei-feng

Abstract

Ether-based solvents generally show better affinity for lithium metal, and thus ether-based electrolytes (EBEs) are more inclined to form a uniform and thin solid electrolyte interface (SEI), ensuring the long cycle stability of the lithium metal batteries (LMBs). Nonetheless, EBEs still face the challenge of oxidative decomposition under high voltage, which will corrode the structure of cathodes, destroy the stability of the electrode-electrolyte interface, and even cause safety risks. Herein, the types and challenges of EBEs are reviewed, the strategies for improving the high voltage stability of EBEs and constructing stable electrode-electrolyte interfaces are discussed in detail. Finally, the future perspectives and potential directions for composition optimization of EBEs and electrolyte-electrode interface regulation of high-voltage LMBs are explored.

Published
2024
Full Text
View/download PDF

21. Erratum To: Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia

Author

He, Bai‐Liang, Yang, Ning, Man, Cheuk Him, Ng, Nelson Ka‐Lam, Cher, Chae‐Yin, Leung, Ho‐Ching, Kan, Leo Lai‐Hok, Cheng, Bowie Yik‐Ling, Lam, Stephen Sze‐Yuen, Wang, Michelle Lu‐Lu, Zhang, Chun‐Xiao, Kwok, Hin, Cheng, Grace, Sharma, Rakesh, Ma, Alvin Chun‐Hang, So, Chi Wai Eric, Kwong, Yok‐Lam, and Leung, Anskar Yu‐Hung

Published
2020
Full Text
View/download PDF

38. Supplementation of tributyrin, alone and in combination with fructooligosaccharide in high soybean meal diets for shrimp ( Litopenaeus vannamei ): Effects on growth, innate immunity and intestinal morphology

Author

Liu, Zi‐Yan, primary, Yang, Hong‐Ling, additional, Yan, Yang‐Yang, additional, Seerengaraj, Vijayaram, additional, Zhang, Chun‐Xiao, additional, Ye, Ji‐dan, additional, Lu, Kang‐Le, additional, and Sun, Yun‐Zhang, additional

Published
2020
Full Text
View/download PDF

42. Follistatin is a novel therapeutic target and biomarker in FLT 3/ ITD acute myeloid leukemia

Author

He, Bai‐Liang, primary, Yang, Ning, additional, Man, Cheuk Him, additional, Ng, Nelson Ka‐Lam, additional, Cher, Chae‐Yin, additional, Leung, Ho‐Ching, additional, Kan, Leo Lai‐Hok, additional, Cheng, Bowie Yik‐Ling, additional, Lam, Stephen Sze‐Yuen, additional, Wang, Michelle Lu‐Lu, additional, Zhang, Chun‐Xiao, additional, Kwok, Hin, additional, Cheng, Grace, additional, Sharma, Rakesh, additional, Ma, Alvin Chun‐Hang, additional, So, Chi Wai Eric, additional, Kwong, Yok‐Lam, additional, and Leung, Anskar Yu‐Hung, additional

Published
2020
Full Text
View/download PDF

45. PAX9 functions as a tumor suppressor gene for cervical cancer via modulating cell proliferation and apoptosis.

Author

Liu, Jie, Wang, Ya‐Qi, Niu, Hai‐Bo, and Zhang, Chun‐Xiao

Subjects
TUMOR suppressor genes, CELL proliferation, INHIBITION of cellular proliferation, APOPTOSIS, EPITHELIAL cells
Abstract

To investigate the effect of PAX9 on the progression of cervical cancer (CC). PAX9 expression was quantified in CC tissues and adjacent normal tissues, as well as human CC cell lines and human cervical epithelial cells (HCerEpiC). PAX9‐overexpression lentiviral vectors were transfected into CC cell lines, followed by the measurement of proliferation and apoptosis and the quantification of apoptosis‐related proteins. In vivo, mice were subcutaneously injected with CaSki cells transfected with PAX9‐overexpression lentiviral vectors and control vectors. Then, the volume and weight of tumors were measured followed by hematoxylin and eosin (HE) staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and immunohistochemistry. PAX9 expression in the CC tissues was lower than that in the adjacent normal tissues, which was correlated with the FIGO stage, tumor size, infiltration depth, parametrium invasion, lympho‐vascular space invasion tumor‐positive lymph nodes, and prognosis. Furthermore, PAX9 in CC cell lines was also lower than in HCerEpiC. PAX9 inhibits the CC cell proliferation and promotes the apoptosis, with the up‐regulations of caspase‐3, poly(ADP‐ribose) polymerase (PARP), and Bax and the down‐regulation of Bcl‐2. In vivo experiments demonstrated that in the PAX9 group, the tumor weight and volume were lower than those in the vector group accompanying the decreased Ki‐67, cleaved‐caspase‐3, and Bax expressions and the increased TUNEL and Bcl‐2 expression. PAX9 was lowly expressed in the CC tissues and associated with the clinicopathological characteristics and prognosis. PAX9 could inhibit proliferation of CC cell lines and promote the apoptosis, thus suppressing the tumor growth in vivo, indicating its potential therapeutic role for CC treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Additional file 1 of Severity and outcomes of influenza-related pneumonia in type A and B strains in China, 2013–2019

Author

Chen, Liang, Xiu-Di Han, Li, Yan-Li, Zhang, Chun-Xiao, and Xi-Qian Xing

Subjects
digestive system, digestive system diseases
Abstract

Additional file 1: Appendix 1. Details of participating centers. Appendix 2. Definition of underlying diseases of patients hospitalized with Flu-p in China, 2013–2019. Definition of microbiological criteria of coinfected with other pathogens in patients hospitalized with Flu-p in China, 2013–2019. Appendix 3. Coinfection with other community-acquired pathogens in patients hospitalized with Flu-p in China, 2013–2019. Appendix 4 Univariate analysis on risk factors for 30-day mortality of patients hospitalized with Flu-p in China, 2013–2019.

Published
2020
Full Text
View/download PDF

47. Long-term outcome of patients with atrial myxoma after surgical intervention: analysis of 403 cases

Author

Jiang, Chen-Xi, Wang, Jian-Gang, Qi, Rui-Dong, Wang, Wei, Gao, Li-Jian, Zhao, Jing-Hua, Zhang, Chun-Xiao, Zhou, Meng-Chen, Tu, Xin, Shang, Mei-Sheng, and Yao, Yan

Subjects
Survival, Atrial myxoma, Embolism, cardiovascular system, cardiovascular diseases, Atrial fibrillation, Research Article
Abstract

Objective To assess long-term survival and late cardiovascular events in patients with atrial myxoma after surgical intervention. Methods Retrospective analysis of 403 patients undergoing resection of atrial myxoma from January 2002 to December 2016 was conducted with a median follow-up period of 4.5 (range: 0.5–15) years. Results The cross-clamp time and cardiopulmonary bypass times were 41.1 ± 21.4 and 65.2 ± 27.3 min, respectively. A diagnosis of myxoma was histopathologically confirmed in all cases. The early in-hospital mortality rate was 0.7% (n = 3). During the follow-up period, tumor recurrence occurred in six patients and cerebral infarction in nine. There were 48 (11.9%) patients with late onset atrial fibrillation (AF). By multivariate analysis, age (HR = 1.05, 95% CI: 1.02–1.09, P < 0.001), left atrial diameter (HR = 1.23, 95% CI: 1.08–1.36, P = 0.012), and mitral valve surgery (HR = 1.17, 95% CI: 1.05–1.29, P = 0.027) were independent predictors of late onset AF. Twenty-one (5.2%) patients died during the follow-up period. Advanced age (HR = 1.07, 95% CI: 1.04–1.10, P = 0.003) and multiple surgical procedures (HR = 1.18, 95% CI: 1.06–1.29, P = 0.012) were significantly associated with overall mortality. Conclusions Atrial myxoma can be resected with good long-term survival. Late onset AF is common after surgery in patients with atrial myxoma. Advanced age, left atrial diameter, and mitral valve surgery were independent predictors of outcomes.

Published
2019

48. Comparison of the Clinical Characteristics and Severity of Influenza and Non-influenza Respiratory Virus-Related Pneumonia in China: A Multicenter, Real-World Study

Author

Chen,Liang, Han,Xiu-Di, Li,Yan-Li, Zhang,Chun-Xiao, Xing,Xi-Qian, Chen,Liang, Han,Xiu-Di, Li,Yan-Li, Zhang,Chun-Xiao, and Xing,Xi-Qian

Abstract

Liang Chen,1 Xiu-Di Han,2 Yan-Li Li,3 Chun-Xiao Zhang,4 Xi-Qian Xing5 1Department of Infectious Diseases, Beijing Jishuitan Hospital, 4th Medical College of Peking University, Beijing, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, Qingdao Municipal Hospital, Qingdao City, Shandong Province, People’s Republic of China; 3Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of China; 4Department of Pulmonary and Critical Care Medicine, Beijing Huimin Hospital, Beijing, People’s Republic of China; 5Department of Pulmonary and Critical Care Medicine, The 2nd People’s Hospital of Yunnan Province, Kunming City, Yunnan Province, People’s Republic of ChinaCorrespondence: Liang Chen Tel +8613810438037Email chenliang1995@sina.comPurpose: Respiratory viruses are important etiologies of community-acquired pneumonia (CAP). However, the impact of different RVs on the outcomes of CAP is not well elucidated. This study aims to compare the clinical features and severity of influenza (Flu-p) and non-influenza respiratory viruses-related pneumonia (NIRVs-p) onset in the community among immunocompetent adults.Methods: The data of the patients hospitalized with laboratory-confirmed RVs-p were retrospectively reviewed from five teaching hospitals in China from January 2013 to May 2019. Univariate and multivariate logistic regressions were performed to compare the clinical characteristics and outcomes between Flu-p and NIRVs-p.Results: A total of 1079 patients with Flu-p and 341 patients with NIRVs-p were included in this study. A multivariate logistic regression model revealed chronic pulmonary disease [odd ratio (OR) 0.341, 95% confidence interval (CI) 0.225– 0.515, p < 0.001], solid malignant tumor (OR 0.330, 95% CI 0.163– 0.668, p = 0.002), myalgia (OR 1.697, 95% CI 1.236&

Published
2020

50. PAX9functions as a tumor suppressor gene for cervical cancer via modulating cell proliferation and apoptosis

Author

Liu, Jie, Wang, Ya‐Qi, Niu, Hai‐Bo, and Zhang, Chun‐Xiao

Abstract

To investigate the effect of PAX9 on the progression of cervical cancer (CC). PAX9 expression was quantified in CC tissues and adjacent normal tissues, as well as human CC cell lines and human cervical epithelial cells (HCerEpiC). PAX9‐overexpression lentiviral vectors were transfected into CC cell lines, followed by the measurement of proliferation and apoptosis and the quantification of apoptosis‐related proteins. In vivo, mice were subcutaneously injected with CaSki cells transfected with PAX9‐overexpression lentiviral vectors and control vectors. Then, the volume and weight of tumors were measured followed by hematoxylin and eosin (HE) staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and immunohistochemistry. PAX9 expression in the CC tissues was lower than that in the adjacent normal tissues, which was correlated with the FIGO stage, tumor size, infiltration depth, parametrium invasion, lympho‐vascular space invasion tumor‐positive lymph nodes, and prognosis. Furthermore, PAX9 in CC cell lines was also lower than in HCerEpiC. PAX9 inhibits the CC cell proliferation and promotes the apoptosis, with the up‐regulations of caspase‐3, poly(ADP‐ribose) polymerase (PARP), and Bax and the down‐regulation of Bcl‐2. In vivo experiments demonstrated that in the PAX9 group, the tumor weight and volume were lower than those in the vector group accompanying the decreased Ki‐67, cleaved‐caspase‐3, and Bax expressions and the increased TUNEL and Bcl‐2 expression. PAX9 was lowly expressed in the CC tissues and associated with the clinicopathological characteristics and prognosis. PAX9 could inhibit proliferation of CC cell lines and promote the apoptosis, thus suppressing the tumor growth in vivo, indicating its potential therapeutic role for CC treatment.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results